Brief: Equillium Inc - Effective Feb 24, Board Increased Number Of Directors To Nine
Brief: Equillium Announces Appointment Of Barbara Troupin To Board Of Directors
Brief: Equillium Acquires Bioniz Therapeutics
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:50 AM
U.S. RESEARCH ROUNDUP-Asana, Coca-Cola, Emerson
Brief: Equillium Announces Publication Of Data On CD6-ALCAM Pathway
Brief: Equillium Announces Data From Phase 1B Equip Study In Patients With Uncontrolled Asthma
Brief: Equillium Announces Additional Patient Data At ASH 2021 Demonstrating Continued Positive And Durable Clinical Responses In Acute Graft-Versus-Host Disease Patients Treated With Itolizumab
Equillium Inc reports results for the quarter ended in September - Earnings Summary
Brief: Equillium Posts Q3 Loss Per Share Of $0.35
Brief: Equillium Presents Interim Safety Data And Reduction In Proteinuria For Lupus Patients Treated With Itolizumab At ACR Annual Meeting
Brief: Equillium Announces Two Abstracts Accepted For Presentation At The Upcoming Virtual 2021 American Society Of Nephrology Annual Meeting
Brief: Equillium Announces Update To EQUALISE Study Of Itolizumab In Patients With Systemic Lupus Erythematosus And Lupus Nephritis
Equillium Inc reports results for the quarter ended in June - Earnings Summary
Brief: Equillium Reports Q2 2021 Financial Results, Provides Clinical Development Update
Equillium Inc expected to post a loss of 31 cents a share - Earnings Preview
Equillium up on plans to advance drug to late-stage trial after FDA input
Brief: Equillium Announces Plans To Initiate Phase 3 Pivotal Study Of Itolizumab In First-Line Treatment Of Acute Graft-Versus-Host Disease Following End-Of-Phase 1 Meeting With The FDA